-
Study: Pfizer, Bristol-Myers Squibb drug for internal blood clots not superior to enoxaparin
NEW YORK — A drug under development by Pfizer and Bristol-Myers Squibb for preventing internal blood clots failed to show superiority over a treatment already on the market, the companies said Monday.
The two drug makers announced Monday results of the phase-3 "ADOPT" study, which was designed to compare the safety and effectiveness of Eliquis (apixaban) with enoxaparin in preventing venous thromboembolism in patients with acute medical illness. Sanofi sells enoxaparin under the brand name Lovenox, and it is available as a generic.